Future developments in the management of malignant pleural mesothelioma (Q37449036)

20 August 2017

1 reference

title

Future developments in the management of malignant pleural mesothelioma (English)

1 reference

20 August 2017

Armando Santoro

4

1 reference

ORCID Public Data File 2021

author name string

Paolo Andrea Zucali

series ordinal

1

1 reference

20 August 2017

Fabio De Vincenzo

series ordinal

2

1 reference

20 August 2017

Matteo Simonelli

series ordinal

3

1 reference

20 August 2017

publication date

1 April 2009

1 reference

Expert Review of Anticancer Therapy

20 August 2017

published in

1 reference

20 August 2017

volume

9

1 reference

20 August 2017

issue

4

1 reference

20 August 2017

page(s)

453-467

1 reference

The pathogenesis of mesothelioma

20 August 2017

cites work

1 reference

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

21 January 2018

1 reference

Biology and management of malignant pleural mesothelioma.

21 January 2018

1 reference

Update on the molecular biology of malignant mesothelioma

21 January 2018

1 reference

Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies

21 January 2018

1 reference

Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.

21 January 2018

1 reference

Radiology in pleural disease: state of the art.

21 January 2018

1 reference

Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.

21 January 2018

1 reference

Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma

21 January 2018

1 reference

Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.

21 January 2018

1 reference

Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging

21 January 2018

1 reference

Positron emission tomography predicts survival in malignant pleural mesothelioma.

21 January 2018

1 reference

The cytology of malignant mesothelioma

21 January 2018

1 reference

Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma

21 January 2018

1 reference

A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.

21 January 2018

1 reference

Use of imaging in the management of malignant pleural mesothelioma

21 January 2018

1 reference

Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma

21 January 2018

1 reference

The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.

21 January 2018

1 reference

MESOMARK: a potential test for malignant pleural mesothelioma

21 January 2018

1 reference

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions

21 January 2018

1 reference

mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats

21 January 2018

1 reference

Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

21 January 2018

1 reference

Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems

21 January 2018

1 reference

External beam radiation therapy for the treatment of pleural mesothelioma

21 January 2018

1 reference

Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest

21 January 2018

1 reference

Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.

21 January 2018

1 reference

A novel radiation therapy technique for malignant pleural mesothelioma combining electrons with intensity-modulated photons.

21 January 2018

1 reference

Chemotherapy options and new advances in malignant pleural mesothelioma

21 January 2018

1 reference

Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis

21 January 2018

1 reference

Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial

21 January 2018

1 reference

A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.

21 January 2018

1 reference

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

21 January 2018

1 reference

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.

21 January 2018

1 reference

Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study

21 January 2018

1 reference

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.

21 January 2018

1 reference

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma

21 January 2018

1 reference

Phase II study of vinflunine in malignant pleural mesothelioma

21 January 2018

1 reference

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma

21 January 2018

1 reference

Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?

21 January 2018

1 reference

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

21 January 2018

1 reference

Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma

21 January 2018

1 reference

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma

21 January 2018

1 reference

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

21 January 2018

1 reference

Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients

21 January 2018

1 reference

Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

21 January 2018

1 reference

Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group

21 January 2018

1 reference

Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.

21 January 2018

1 reference

Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.

21 January 2018

1 reference

Modeling of mesothelioma growth demonstrates weaknesses of current response criteria.

21 January 2018

1 reference

New technologies and directed agents for applications of cancer imaging

21 January 2018

1 reference

Positron emission tomography as an imaging biomarker

21 January 2018

1 reference

Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer

21 January 2018

1 reference

21 January 2018

1 reference

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

21 January 2018

1 reference

VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.

21 January 2018

1 reference

Using Gene Expression Ratios to Predict Outcome Among Patients With Mesothelioma

21 January 2018

1 reference

Validation of genomics-based prognostic tests in malignant pleural mesothelioma

21 January 2018

1 reference

Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer

21 January 2018

1 reference

Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.

21 January 2018

1 reference

SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure.

21 January 2018

1 reference

Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase.

21 January 2018

1 reference

Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt pathway

21 January 2018

1 reference

Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth

21 January 2018

1 reference

Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development

21 January 2018

1 reference

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

21 January 2018

1 reference

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study

21 January 2018

1 reference

Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.

21 January 2018

1 reference

Regulation of differential expression of platelet-derived growth factor alpha- and beta-receptor mRNA in normal and malignant human mesothelial cell lines

21 January 2018

1 reference

Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts

21 January 2018

1 reference

Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed

21 January 2018

1 reference

Antiangiogenic therapies for mesothelioma

21 January 2018

1 reference

Thalidomide in patients with malignant pleural mesothelioma

21 January 2018

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

The Met pathway: master switch and drug target in cancer progression

21 January 2018

1 reference

Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma.

21 January 2018

1 reference

SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma

21 January 2018

1 reference

Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion

21 January 2018

1 reference

Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid

21 January 2018

1 reference

Bortezomib as a potential treatment for prostate cancer

21 January 2018

1 reference

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

21 January 2018

1 reference

Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma

21 January 2018

1 reference

Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas

21 January 2018

1 reference

Molecular pathways in malignant pleural mesothelioma

21 January 2018

1 reference

Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma.

21 January 2018

1 reference

Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma

21 January 2018

1 reference

Mesothelin targeted cancer immunotherapy

21 January 2018

1 reference

Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts

21 January 2018

1 reference

Cancer chemotherapy--ribonucleases to the rescue

21 January 2018

1 reference

Mesothelin-family proteins and diagnosis of mesothelioma

21 January 2018

1 reference

Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.09.2

1 reference

20 August 2017

1 reference